ALPINE IMMUNE SCIENCES INC's ticker is ALPN and the CUSIP is 02083G100. A total of 59 filers reported holding ALPINE IMMUNE SCIENCES INC in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $6,933,490 | +17.7% | 605,545 | +5.7% | 0.00% | – |
| Q2 2023 | $5,888,816 | +120.0% | 572,842 | +65.2% | 0.00% | – |
| Q1 2023 | $2,676,300 | -40.0% | 346,671 | -42.9% | 0.00% | – |
| Q4 2022 | $4,460,244 | +122.0% | 606,836 | +117.5% | 0.00% | – |
| Q3 2022 | $2,009,000 | -11.9% | 278,982 | +4.1% | 0.00% | – |
| Q2 2022 | $2,281,000 | +15.3% | 268,082 | +21.5% | 0.00% | – |
| Q1 2022 | $1,979,000 | -30.6% | 220,621 | +7.1% | 0.00% | – |
| Q4 2021 | $2,853,000 | +35.2% | 206,012 | +4.2% | 0.00% | – |
| Q3 2021 | $2,110,000 | +35.4% | 197,796 | +14.3% | 0.00% | – |
| Q2 2021 | $1,558,000 | +2334.4% | 173,119 | +1609.6% | 0.00% | – |
| Q3 2018 | $64,000 | – | 10,126 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Decheng Capital Management III (Cayman), LLC | 6,708,288 | $76,809,898 | 25.63% |
| Lynx1 Capital Management LP | 2,404,614 | $27,532,830 | 18.21% |
| GREAT POINT PARTNERS LLC | 3,078,633 | $35,250,348 | 6.42% |
| Ghost Tree Capital, LLC | 664,132 | $7,604,311 | 2.50% |
| Frazier Life Sciences Management, L.P. | 2,985,757 | $34,186,918 | 2.27% |
| Paradigm Biocapital Advisors LP | 2,421,743 | $27,728,957 | 1.88% |
| COMMODORE CAPITAL LP | 1,325,000 | $15,171,250 | 1.77% |
| Nan Fung Group Holdings Ltd | 182,280 | $2,087,106 | 1.69% |
| Omega Fund Management, LLC | 153,700 | $1,759,865 | 1.62% |
| Octagon Capital Advisors LP | 750,000 | $8,587,500 | 1.32% |